These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 30025993)

  • 1. [Adaptation of platelet concentrates delivery to HAS/ANSM requirements evolution in EFS Grand-Est].
    Kientz D; Humbrecht C; Isola H; Gachet C
    Transfus Clin Biol; 2018 Sep; 25(3):187-191. PubMed ID: 30025993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparative study on platelet transfusion in Lorraine-Champagne and Alsace in 2015].
    Humbrecht C; Somme S; Renaudier P; Gross S; Gachet C; Schlanger S
    Transfus Clin Biol; 2018 Sep; 25(3):179-186. PubMed ID: 30076013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of CONSORT compliance in TRANSFUSION.
    Jaffer AM; Wang G; Barty RL; Shih AW
    Transfusion; 2016 Apr; 56(4):789-90. PubMed ID: 26612765
    [No Abstract]   [Full Text] [Related]  

  • 4. Pathogen inactivation/reduction technologies for platelet transfusion: Where do we stand?
    Garraud O; Lozano M
    Transfus Clin Biol; 2018 Sep; 25(3):165-171. PubMed ID: 30041847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet utilization and the transfusion trigger: a prospective analysis.
    Greeno E; McCullough J; Weisdorf D
    Transfusion; 2007 Feb; 47(2):201-5. PubMed ID: 17302764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consensus and controversies in platelet transfusion.
    Marwaha N; Sharma RR
    Transfus Apher Sci; 2009 Oct; 41(2):127-33. PubMed ID: 19717344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Blood components and good practices in transfusion].
    Andreu G
    Presse Med; 2015 Feb; 44(2):165-77. PubMed ID: 25542709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do Physicians Adhere to Platelet Transfusion Guidelines?
    Sedhom R; Willett L
    Am J Med Qual; 2016 Jul; 31(4):383. PubMed ID: 27012607
    [No Abstract]   [Full Text] [Related]  

  • 9. [Pathogen inactivation in platelet concentrates: the French experience].
    Cazenave JP
    Transfus Clin Biol; 2011 Aug; 18(4):478-84. PubMed ID: 21719338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The platelet prophylactic transfusion trigger: when expectations meet reality.
    Brecher ME
    Transfusion; 2007 Feb; 47(2):188-91. PubMed ID: 17302761
    [No Abstract]   [Full Text] [Related]  

  • 11. [Feasibility study for Intercept platelets].
    Bardiaux L; Vauzou S; Olivier B; Mathieu-Daude D; Durand E; Dite C; Roubinet F
    Transfus Clin Biol; 2016 Nov; 23(4):212-216. PubMed ID: 27644172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Practice assessment in platelet transfusions].
    Martinaud C; Chastagnet N; Sailliol A; de Jaureguiberry JP; Aguilon P
    Transfus Clin Biol; 2012 Feb; 19(1):25-31. PubMed ID: 22284451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence to NICU transfusion guidelines: data from a multihospital healthcare system.
    Baer VL; Lambert DK; Schmutz N; Henry E; Stoddard RA; Miner C; Wiedmeier SE; Burnett J; Eggert LD; Christensen RD
    J Perinatol; 2008 Jul; 28(7):492-7. PubMed ID: 18337739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of bacterial contamination in platelet concentrates at the National Center of Blood Transfusion (Mexico).
    Ibáñez-Cervantes G; Bello-López JM; Fernández-Sánchez V; Domínguez-Mendoza CA; Acevedo-Alfaro LI
    Transfus Clin Biol; 2017 Jun; 24(2):56-61. PubMed ID: 28412024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of processing characteristics of photochemically treated pooled platelets: target requirements for the INTERCEPT Blood System comply with routine use after process optimization.
    Picker SM; Speer R; Gathof BS
    Transfus Med; 2004 Jun; 14(3):217-23. PubMed ID: 15180813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet transfusion practice during dengue fever epidemic.
    Kumar ND; Tomar V; Singh B; Kela K
    Indian J Pathol Microbiol; 2000 Jan; 43(1):55-60. PubMed ID: 12583421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of reasons for not implementing pathogen inactivation for platelet concentrates.
    Lozano M; Cid J
    Transfus Clin Biol; 2013 May; 20(2):158-64. PubMed ID: 23587612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates.
    Kaiser-Guignard J; Canellini G; Lion N; Abonnenc M; Osselaer JC; Tissot JD
    Blood Rev; 2014 Nov; 28(6):235-41. PubMed ID: 25192602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evaluation of the concordance between guidelines and transfusion practices in neonatal intensive care units].
    Royon V; Lardennois C; Maréchal I; Dureuil B; Marret S; Laudenbach V
    Ann Fr Anesth Reanim; 2012 Jun; 31(6):517-22. PubMed ID: 22464838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet dosing.
    Schlossberg HR; Herman JH
    Transfus Apher Sci; 2003 Jun; 28(3):221-6. PubMed ID: 12725947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.